DiaMedica Therapeutics (NASDAQ:DMAC) Trading 3.7% Higher

DiaMedica Therapeutics Inc. (NASDAQ:DMAC)’s share price traded up 3.7% on Friday . The stock traded as high as $3.15 and last traded at $3.06. 83,802 shares traded hands during mid-day trading, a decline of 3% from the average session volume of 86,609 shares. The stock had previously closed at $2.95.

Analysts Set New Price Targets

Separately, Oppenheimer raised shares of DiaMedica Therapeutics from a “market perform” rating to an “outperform” rating and set a $7.00 price objective on the stock in a research note on Thursday, June 22nd.

DiaMedica Therapeutics Price Performance

The firm has a market cap of $116.13 million, a price-to-earnings ratio of -4.94 and a beta of 1.87. The firm’s fifty day moving average is $3.44 and its 200-day moving average is $2.51.

Insider Activity at DiaMedica Therapeutics

In other news, CEO Dietrich John Pauls bought 12,787 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The shares were acquired at an average price of $3.91 per share, for a total transaction of $49,997.17. Following the completion of the acquisition, the chief executive officer now directly owns 68,591 shares in the company, valued at $268,190.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Dietrich John Pauls acquired 12,787 shares of the company’s stock in a transaction dated Friday, June 23rd. The shares were purchased at an average price of $3.91 per share, for a total transaction of $49,997.17. Following the completion of the acquisition, the chief executive officer now owns 68,591 shares of the company’s stock, valued at $268,190.81. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Scott Kellen acquired 10,000 shares of the company’s stock in a transaction dated Friday, June 23rd. The shares were bought at an average price of $3.91 per share, for a total transaction of $39,100.00. Following the acquisition, the chief financial officer now directly owns 32,290 shares of the company’s stock, valued at approximately $126,253.90. The disclosure for this purchase can be found here. Insiders have bought a total of 1,596,739 shares of company stock worth $5,493,250 over the last quarter. Company insiders own 6.50% of the company’s stock.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Cooperman Leon G raised its holdings in shares of DiaMedica Therapeutics by 0.9% in the 2nd quarter. Cooperman Leon G now owns 875,993 shares of the company’s stock worth $3,784,000 after acquiring an additional 7,580 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of DiaMedica Therapeutics in the 2nd quarter worth about $57,000. BNP Paribas Arbitrage SNC raised its holdings in shares of DiaMedica Therapeutics by 344.6% in the 2nd quarter. BNP Paribas Arbitrage SNC now owns 9,800 shares of the company’s stock worth $42,000 after acquiring an additional 7,596 shares during the last quarter. Catalyst Financial Partners LLC raised its holdings in shares of DiaMedica Therapeutics by 44.4% in the 2nd quarter. Catalyst Financial Partners LLC now owns 36,267 shares of the company’s stock worth $157,000 after acquiring an additional 11,157 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of DiaMedica Therapeutics by 91.9% in the 1st quarter. Renaissance Technologies LLC now owns 64,508 shares of the company’s stock worth $99,000 after acquiring an additional 30,889 shares during the last quarter. Institutional investors and hedge funds own 6.42% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke.